PCOS has been officially renamed PMOS. Here is why the change matters and what it means for diagnosis and care.
Polycystic ovary syndrome (PCOS) has a new name: polyendocrine metabolic ovarian syndrome (PMOS). The change is not cosmetic. It reflects a more accurate understanding of the condition and its health implications.
What Changed and Why
The new name, PMOS, was announced in May 2026 through a global consensus statement published in The Lancet. The decision followed about 14 years of campaigning and consultation with more than 56 organisations and over 22,000 participants. Australian groups, including Monash University and RANZCOG, were heavily involved.
The old name, polycystic ovary syndrome, was misleading. Many women with the condition do not have ovarian cysts, and cystic-looking ovaries can occur without the syndrome. The new name better captures three key features:
Polyendocrine: multiple hormonal systems are involved.
Metabolic: insulin resistance, higher risk of type 2 diabetes and cardiovascular disease are central.
Ovarian: the ovaries are part of the picture, but not the whole story.
What This Means in Practice
For now, you will see both terms used together, for example "PCOS (now termed PMOS)." A three-year transition period is under way, with full adoption in the International Guideline expected by 2028. Australian colleges and health organisations, including RANZCOG, RACGP, and Diabetes WA, are already using the new name.
If you have been diagnosed with PCOS, your diagnosis remains valid. The name change does not alter your treatment plan. What it does is shift the focus toward the metabolic and hormonal aspects, which are often the drivers of long-term health outcomes.
Why the Metabolic Part Matters
Insulin resistance affects up to 75% of women with PMOS. This is not just about weight. It increases the risk of type 2 diabetes, high blood pressure, and abnormal cholesterol. Cardiovascular disease is a leading cause of death in women with PMOS, yet it is often under-recognised.
The new name puts metabolic health front and centre. That means screening for blood glucose, lipids, and blood pressure should be a routine part of care. Lifestyle interventions, particularly strength training and dietary changes, are among the most effective strategies for improving insulin sensitivity and reducing long-term risk.
What Has Not Changed
Diagnosis still relies on the Rotterdam criteria: two of three features (irregular periods, signs of high androgens, or polycystic ovaries on ultrasound). Treatment remains individualised. It may include lifestyle changes, medications for insulin resistance or hormonal symptoms, and support for fertility if needed.
The name change does not introduce new treatments. It reframes the condition so that care can be more comprehensive.
What You Can Do
If you have PMOS, or think you might, here are the evidence-based steps worth discussing with your GP:
Get a baseline metabolic screen: fasting glucose, HbA1c, lipids, and blood pressure.
Consider a glucose tolerance test if you have additional risk factors.
Prioritise resistance training and adequate protein intake. Muscle mass improves insulin sensitivity.
Address sleep and stress. Both affect hormone regulation and metabolic health.
The Bottom Line
PMOS is a more accurate name for a condition that affects about 1 in 10 women. The change highlights that this is not just a reproductive issue. It is a metabolic and hormonal condition with implications for heart health, diabetes risk, and overall wellbeing.
The evidence is clear: early recognition and proactive management of the metabolic components can reduce long term complications. That is the real takeaway, regardless of what you call it.
General information, not individual medical advice. Speak to your own doctor.